IL-37 up-regulation can reduce inflammation and alleviate IBD symptoms in dextran sodium sulfate (DSS)-induced colitis model, indicating that IL-37 or its regulatory factors are a promising target for IBD treatment (86, 87). This evidence concerns the gene IL37 and inflammatory bowel disease.